📊 LYEL Key Takeaways
Is Lyell Immunopharma, Inc. (LYEL) a Good Investment?
Lyell Immunopharma is a clinical-stage biotech company with minimal revenue ($2K) and substantial operating losses (-$44.3M). While the company maintains a strong balance sheet with $90.8M in cash and no debt providing approximately 2+ years of runway, the rapid cash burn rate (-$38.5M operating cash flow) combined with pre-commercial stage operations creates significant execution risk without demonstrated clinical trial success or partnership milestones.
Lyell Immunopharma’s fundamentals are extremely weak: revenue is negligible, operating losses remain massive, and free cash flow is deeply negative relative to the size of the business. While the balance sheet shows no long-term debt and a strong current ratio, the cash burn appears unsustainably high versus cash on hand, making funding risk the dominant fundamental issue.
Why Buy Lyell Immunopharma, Inc. Stock? LYEL Key Strengths
- Strong balance sheet with $273.7M stockholders' equity and zero debt
- Solid cash position ($90.8M) providing operational runway
- Excellent current ratio of 7.23x indicates short-term liquidity strength
- No long-term debt obligations limiting financial distress risk near-term
- Debt-free balance sheet reduces financial leverage risk
- Current and quick ratios of 5.28x indicate solid near-term liquidity on paper
- Net loss and diluted EPS improved year over year, suggesting some reduction in bottom-line pressure
LYEL Stock Risks: Lyell Immunopharma, Inc. Investment Risks
- Minimal revenue generation ($2K) indicates pre-commercial stage with unproven commercialization
- Annual operating cash burn of $38.5M with limited runway relative to typical biotech development timelines
- Negative operating and net margins (-2.2M% and -1.2M% respectively) indicating far from profitability
- Clinical-stage risk: success dependent on trial outcomes, regulatory approval, and market adoption
- Capital requirements likely to increase as pipeline advances through development stages
- Business remains essentially pre-commercial with only $36K of revenue and no demonstrated operating scale
- Operating cash outflow of $150.02M far exceeds cash reserves of $60.18M, implying severe runway pressure
- Profitability is structurally weak, with deeply negative operating margin, net margin, ROE, and ROA
Key Metrics to Watch
- Operating cash burn rate trend and projected runway duration
- Clinical trial progress and regulatory milestones for lead candidates
- Quarterly revenue growth and commercial partnerships or licensing deals
- Cash position and financing activities for future capital raises
- Quarterly operating cash burn versus cash and equivalents
- Revenue traction and any sustained reduction in operating loss
Lyell Immunopharma, Inc. (LYEL) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 7.23x current ratio provides a solid financial cushion.
LYEL Profit Margin, ROE & Profitability Analysis
LYEL vs Healthcare Sector: How Lyell Immunopharma, Inc. Compares
How Lyell Immunopharma, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Lyell Immunopharma, Inc. Stock Overvalued? LYEL Valuation Analysis 2026
Based on fundamental analysis, Lyell Immunopharma, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Lyell Immunopharma, Inc. Balance Sheet: LYEL Debt, Cash & Liquidity
LYEL Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Lyell Immunopharma, Inc.'s revenue has declined by 99% over the 5-year period, indicating business contraction. The most recent EPS of $-18.70 indicates the company is currently unprofitable.
LYEL Revenue Growth, EPS Growth & YoY Performance
LYEL Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $2.0K | -$24.2M | $-1.10 |
| Q3 2025 | $15.0K | -$38.8M | $-2.13 |
| Q2 2025 | $8.0K | -$42.7M | $-2.89 |
| Q1 2025 | $3.0K | -$52.2M | $-0.18 |
| Q3 2024 | $25.0K | -$44.6M | $-0.17 |
| Q2 2024 | $13.0K | -$45.8M | $-0.18 |
| Q1 2024 | $3.0K | -$60.7M | $-0.24 |
| Q3 2023 | $3.0K | -$50.9M | $-0.20 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Lyell Immunopharma, Inc. Dividends, Buybacks & Capital Allocation
LYEL SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Lyell Immunopharma, Inc. (CIK: 0001806952)
📋 Recent SEC Filings
❓ Frequently Asked Questions about LYEL
What is the AI rating for LYEL?
Lyell Immunopharma, Inc. (LYEL) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (STRONG SELL) with 80% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are LYEL's key strengths?
Claude: Strong balance sheet with $273.7M stockholders' equity and zero debt. Solid cash position ($90.8M) providing operational runway. ChatGPT: Debt-free balance sheet reduces financial leverage risk. Current and quick ratios of 5.28x indicate solid near-term liquidity on paper.
What are the risks of investing in LYEL?
Claude: Minimal revenue generation ($2K) indicates pre-commercial stage with unproven commercialization. Annual operating cash burn of $38.5M with limited runway relative to typical biotech development timelines. ChatGPT: Business remains essentially pre-commercial with only $36K of revenue and no demonstrated operating scale. Operating cash outflow of $150.02M far exceeds cash reserves of $60.18M, implying severe runway pressure.
What is LYEL's revenue and growth?
Lyell Immunopharma, Inc. reported revenue of $2.0K.
Does LYEL pay dividends?
Lyell Immunopharma, Inc. does not currently pay dividends.
Where can I find LYEL SEC filings?
Official SEC filings for Lyell Immunopharma, Inc. (CIK: 0001806952) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is LYEL's EPS?
Lyell Immunopharma, Inc. has a diluted EPS of $-1.10.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is LYEL a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Lyell Immunopharma, Inc. has a SELL rating with 80% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is LYEL stock overvalued or undervalued?
Valuation metrics for LYEL: ROE of -8.8% (sector avg: 15%), net margin of -1,207,650.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy LYEL stock in 2026?
Our dual AI analysis gives Lyell Immunopharma, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is LYEL's free cash flow?
Lyell Immunopharma, Inc.'s operating cash flow is $-38.5M, with capital expenditures of $89.0K. FCF margin is -1,929,950.0%.
How does LYEL compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1,207,650.0% (avg: 12%), ROE -8.8% (avg: 15%), current ratio 7.23 (avg: 2).